ZYBERNO
Stock Report
Updated Jun 8, 2026

EVOKE PHARMA, INC. (EVOK)

Healthcare • NASDAQ

$11.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
24.0/100
POOR BUSINESS
EVOKE PHARMA, INC. (EVOK) scores 24/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-101.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.07x)
Operating Margin (Operational Efficiency):CRITICAL (-36.0%)
Return on Capital (Capital Efficiency):CRITICAL (-95.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

EVOKE PHARMA, INC. (EVOK) stock report — Zyberno Score 24/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:11.00
Market Cap:$28.13M

Valuation Multiples (3)

P/B Ratio:8.37x
P/S Ratio:1.95x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$20.52M
B. Profitability Assessment

Return Metrics (5)

ROA:-31.9%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (3)

Operating Margin Ttm:-36.0%
Net Margin Ttm:-36.2%
Ebitda Margin:-36.0%

TTM Performance (2)

Operating Margin Ttm:-36.0%
Net Margin Ttm:-36.2%

Yield Metrics (2)

Earnings Yield:-$21.36
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:57.2%
Latest Earnings Filed:2025-11-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):96.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.27x
Quick Ratio:1.22x
Cash Ratio:0.95x

Leverage Analysis (3)

Debt To Equity Ttm:0.07x
Debt-to-Equity Ratio:0.07x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-10.41x
Times Interest Earned:-10.41

Capital Structure (4)

Working Capital:3,295,591.00
Cash And Cash Equivalents:11,576,010.00
Long Term Debt:$46.38K
Net Debt:-$7.61M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $14.42M
Linear Growth: 96.0%
📊 Click to view full EVOK Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$5.19M

Bottom Line Performance (3)

-$5.23M
Income Before Tax:$0.00
Ebitda Ttm:-5,191,981.00

Operating Expenses (5)

Operating Expenses:19,616,633.00
R And D Expense:61,161.00
Sga Expense:19,130,348.00
Income Tax Expense:$0.00
Interest Expense:500,001.00

Expense Ratios (3)

R And D To Revenue Percentage:1.4%
Sga To Revenue Percentage:446.6%
Ebitda Margin:-36.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$15.65M
Current Assets:$15.54M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:12,287,197.00
Current Liabilities:12,240,816.00
Long Term Debt:$46.38K
Short Term Debt:$3.92M

Equity & Capital (3)

Equity:$3.36M
Retained Earnings:-$132.82M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:3,190,486.00
Inventory:599,908.00
Accounts Payable:3,916,295.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:105,056.00
C. Cash Flow Analysis

Operating Activities (2)

-$3.88M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$25.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.35
-$2.35
Earnings Per Share Ttm:-$2.04

Revenue & Cash Per Share (2)

Sales Per Share Ttm:5.64
Operating Cash Flow Per Share:-$2.13

Book Value & Capital (2)

Book Value Per Share:$1.31
Cash Per Share:4.53

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.88x
Working Capital Turnover Ttm:4.38x

Receivables Management (2)

Receivables Turnover Ttm:4.52x
Days Sales Outstanding Ttm:80.73

Inventory Management (2)

Inventory Turnover Ttm:24.04x
Days Inventory Outstanding Ttm:15.18

Payables & Cash Cycle (2)

Days Payable Outstanding:99.10
Cash Conversion Cycle:-3.19
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):96.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):1.5%
C. Company Profile & Context

Corporate Information (6)

Symbol:EVOK
Company Name:EVOKE PHARMA, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:2.56M
Shares Outstanding Basic:2.56M
Shares Outstanding Diluted:2.56M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-08 11:09:20 UTC
Data Timestamp:2026-06-08T11:09:20.600127
Scroll to Top